7 studies found for:    20525992 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Condition: Melanoma
Intervention: Drug: vemurafenib and cobimetinib
2 Active, not recruiting Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood
Condition: Childhood Solid Tumor
Interventions: Biological: AV0113 DC-CIT;   Other: Data evaluation
3 Recruiting Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Conditions: Head and Neck Squamous Cell Carcinoma;   Metastatic Renal Cell Cancer;   Recurrent Head and Neck Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Skin Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Lung Cancer;   Stage IV Skin Melanoma
Interventions: Radiation: Radiation Therapy (RT);   Drug: MK-3475
4 Active, not recruiting Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases
Conditions: Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Drug: Ipilimumab;   Radiation: Whole-Brain Radiation Therapy (WBRT);   Radiation: Stereotactic Radiosurgery (SRS)
5 Completed A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
Condition: Metastatic Malignant Melanoma
Intervention: Drug: Ipilimumab and Fotemustine
6 Active, not recruiting Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
Condition: Malignant Melanoma, Metastatic
Interventions: Biological: Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF);   Biological: Ipilimumab
7 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine

Indicates status has not been verified in more than two years